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The diverse biological consequences of size-expansion of the unstable (CTG)n repeat in the myotonic 
dystrophy protein kinase (DM-PK) gene at chromosome region 19q13.3, are still poorly understood. Abnormal 
(CTG)n length may affect either DM-PK mRNA fate or function, or alternatively, compromise gene transcription 
by distortion of chromatin configuration. In the latter model involvement of neighbouring genes in DM upon 
extreme expansion of the repeat cannot be discarded as a possibility and should be studied further. Here we 
report on the elucidation of the complete genomic structure and expression pattern of the mouse DMR-N9 
gene (called 59 gene in humans), which is at 1.1 kbp upstream of the DM-PK gene. This gene contains five 
exons spanning 7 kbp and codes for a protein of 650 amino acids. Two regions of the predicted protein show 
significant homology to WD repeats, highly conserved amino acid sequences found in a family of proteins 
engaged in signal transduction or cell regulatory functions. The start site of transcription has been determined 
and we have identified putative transcription factor binding sequences in a 400 bp putative promoter area 
immediately upstream of the transcribed unit. Northern blotting analysis and RNA in situ hybridization revealed 
ubiquitous low expression in all tissues of the mouse embryo and enhanced expression in adult brain and 
testis. The onset of transcription is phased early in mouse embryogenesis, before or at day 9.5 of gestation. 
From day 14.5 onwards DMR-N9 mRNAs were detected in all neural tissues, especially in the telencephalon 
and mesencephalon. Later, mRNA presence is evident In distinct tubules of the mature testis, restricted to 
secondary spermatocytes of stages VIII to XII of the spermatogenic proliferation cycle. We conclude that the 
DMR-N9 gene is a candidate for being involved in the manifestation of mental and testicular symptoms in 
severe cases of DM.
developmental expression pattern
INTRODUCTION
Myotonic dystrophy, the most common form of muscular 
dystrophy in adults (I), is caused by the expansion of an 
unstable CTG trinucleotide repeat (2-4). Manifestation of the 
DM phenotype is correlated— but not tautly— with the repeat 
length as determined from blood DNA (5-7). Generally, 
patients with 40-150 CTGs show no or only very mild 
symptoms (cataract) and carriers of repeats up to a thousand 
CTGs are more severely affected, with muscular dystrophy, 
atrophy, myotonia and variable multi-organ dysfunctioning. In
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the most severe form of DM, seen in congenital and early onset 
cases which carry even larger alleles, additional involvement of 
mental retardation and serious defects in endocrine functions 
are commonly observed.
The expanding (CTG)n repeat is located in the 3' untranslated 
region of the DM protein kinase gene (DM-PK) in a gene- 
dense area on human chromosome 19ql3.3. Elucidation of the 
structural organization and expression pattern of this gene in 
human and mouse has revealed interesting clues about its
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possible part in muscle functioning (2—4,8-12), but it is still 
unclear if the DM-PK gene is the only gene involved in DM. 
Both over- and under-expression, as well as unaltered DM-PK
expression have been reported (11,13-18; M.Siciliano, personal 
communication). Until now, no changes in the level and nature 
of mRNAs or protein products of other genes from within the
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exon 4 exon 5
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CACATACTGGGGGTCCCCTA GGTTGGCCCAGCCATGGGGA TGTAGTGTCCTGTGTGGCCT TGGCCCTTGGTTCCTCCACC CACTGCCAAGTACAATGACC 2700
TGTTCTCTGAAACATCAGTG TTAACCATATCCCTGTCCCA GCATGTGACTGTTCACTCCT GGGAGAGACTTAGCCCACAG TACCCCTGGGTGAGAGGGCA 2800
GGGCAGGGGCCATCCCCACT CCTGCCCAAACCCCACCCCT TGCTATGGTCTGTGATTTTG AAAGTGTTAAATTATGGAAG CCCTGAGGGCCCTCCTTGTT 2900
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Figure 1. Essential sequences across the mouse DMR-N9 gene region. (A) Sequences of the 5' end of the mouse DMR-N9 gene, the cDNAs, the predicted 
primary structure of the gene product, and the 3' end up to the DM-PK translation start site. Transcribed sequences are in capitals. The /towHI, Nhel and Ncol 
sites used to generate probes for the S r  nucl ease assays are doubly underlined and the binding site of the primer elongation oligonucleotide is indicated (PE 
primer). The putative CAAT box, several putative transcription factor binding sites (indicated underneath the sequences), the ATG start codons, and the four 
internal WD-rcpeat domains (positions 191-225; 262-297; 301-337 and 386-422) are shaded. Transcription initiation sites, as well as the 5' end of the 1.4, 9.1 
and human cDNA clones, are indicated by arrows. Boundaries of exons are shown by vertical lines, with the beginning and end of each exon numbered. The 
two polyadenylation signals are underlined. (B ) Alignment of the partial DMR-N9 WD repeats with the WD-repeat consensus sequence proposed by Neer et al. 
(24) and van der Voorn and Ploegh (25). Any one of the amino acids of the consensus in a vertical column may occur at that position (X is any amino acid). 
Conservative positions in the WD repeat are underlined. Homology (shaded positions) is most significant in the C-terminal portion of each DMR-N9 repeat 
unit (underlined). Similar partial repeat conservation has been found in other proteins (25).
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DM critical area have been described. Theoretically, we may 
expect such changes to result from titration of DNA or RNA 
binding proteins (19), or alterations in the chromatin structure 
around the expanded repeat (20).
A possible candidate gene which might be involved in 
severe manifestation of myotonic dystrophy, the DMR-N9 
gene (8,9) or 59 gene (10), was identified when the search for 
the DM mutation culminated, This gene is located very close 
to the DM-PK gene, at approximately 1100 bp upstream, and 
is prominently expressed in brain and testis, two tissues which 
are commonly affected in DM patients. Here we report on the 
characterization of the complete mouse DMR-N9 transcription 
unit, including the promoter, transcription start site and intron/ 
exon boundaries. The expression distribution of the mouse 
DMR-N9 gene during development was studied in detail by 
Northern blot analysis and in situ hybridization on mouse 
tissues. We discuss clues on its function and the possible 
significance of our data for the understanding of the complex 
clinical picture of DM.
RESULTS
Genetic characterization of DMR-N9
Upon screening of a mouse brain cDNA library with the 5' 
end of the previously described DMR-N9 cDNA (clone 9.1; 
ref. 8) a new clone was isolated which extended the transcribed 
region to 205 bp further upstream (clone 1.4; Fig. 1A). 
However, as this sequence did not contain a putative translation 
start codon, we concluded that clone 1.4 still did not represent 
a full length transcript. Unfortunately, attempts to isolate full 
length cDNAs from other sources have not been successful 
until now.
In order to fully characterize the DMR-N9 gene, a detailed 
restriction map of the relevant region of cosmid mc8, located 
on mouse chromosome 7 (21) was generated (Fig. 2). The 
DMR-N9 gene maps within a region of only 7 kbp, of which 
several overlapping subclones were partially sequenced (EMBL 
accession numbers Z38011— Z38013 and Z38015). By compar­
ing the genomic and cDNA sequences we were able to delineate 
five exons (Figs 1A and 2), which range in size from 75 to 
1260 bp. The exon—intron boundaries, which flank introns 
between 280 and 1830 bp in size, comply with the GT/AG 
rule for 5' and 3' splice site sequences (Table 1). As the cDNA 
analysis failed to indicate the genes 5 ' end we extended our 
genomic sequence to 570 bp upstream of the longest cDNA.
In this region, which is extremely C/G rich, we found a 
putative translation start codon at only 40 bp upstream of the 
5' cDNAend (CCGCCATGG), Because the sequence flanking 
this possible start codon is identical to the Kozak consensus 
sequence (22), computer prediction strongly favours this ATG 
over a second ATG start codon, located 45 bp further upstream 
(CCAAGATGG). If true, the DMR-N9 gene encodes a protein 
of 650 amino acids, with a molecular weight of 68 660 Daltons, 
Also the genes 3' side, in the region between DMR-N9 and 
DM-PK (or DMR-B15 as designated in ref. 8) was sequenced 
completely (positions 2940-4016 in Fig. 1A; EMBL accession 
number Z38015). The most downstream DMR-N9 polyadenyi- 
ation site as deduced from mouse cDNAs is positioned at only 
1240 bp upstream of the DM-PK translation start codon. As 
we have preliminary evidence that the 5' UTR in the mouse 
DM-PK gene spans approximately 140 bp, which is signific­
antly shorter than the 5' UTR in the human situation (9), we 
conclude that the end of DMR-N9 and the start site of 
transcription in the DM-PK gene in mouse are 1077 bp apart.
DMR-N9 transcription
To verify the computer predictions and to determine the length 
of the putative first exon more precisely, an S|-nuclease 
protection assay on DMR-N9 mRNA was performed. To avoid 
interference from the extremely high frequency and patchy 
distribution of C/Gs in the relevant region (87% C/G in the 
100 bp 5' to the ATG; Fig. 1A) we used two different 
probes and tested various hybridization temperatures. Probe
A, generated from a genomic BamHl—Ncol subclone which 
spans the complete cloned region upstream of the ATG, 
including the C/G rich area, yielded a doublet signal of 
protected fragments of 112 and 118 nucleotides (Fig. 3) in 
mouse brain, liver, intestine and testis RNA, but not in 
Escherichia coli control RNA. The signal intensities varied 
with the expression levels as seen on Northern blots (see Fig. 
4). We can exclude artefacts due to preferential domain melting 
of our probe, as we saw no signals from probe portions 
hybridizing to another C/G rich clamp area (65% C/G) 100 
bp further upstream. Also when the location of the start site 
of transcription was verified with an end-labelled probe, probe
B, which ends at the NheI site at position 410, no S|-resistant 
fragments could be seen after test hybridizations between 55 
and 65°C. Likewise, primer elongation experiments (primer 
overlapping the Nhel site in probe B) did not yield extended 




















Figure 2* Structural organization and restriction map of the mouse DMR-N9 gene. The DMR-N9 exons are depicted as open boxes, the translation start codon
is indicated with an arrow, the translation stop codon with a star. The first exon of the DM-PK gene is given as a black box. Restriction sites- B Z taH I;  H, 
Hind\U\ N, Ncol\ S, Sail, X, Xhol.
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MATERIALS AND METHODS
Characterization of cosmids and cDNAs
The isolation of mouse cosmici (mouse strain 129/Sv) and cDNA clones has 
been described elsewhere (8). Using the 5' end of a fully characterized 
DMR-N9 cDNA clone (clone 9.1; ref. 8) as a probe, additional cDNA clones 
were isolated from the original mouse brain cDNA library (Stratagene). 
Restriction enzyme mapping and sequencing using the supercoiled DNA 
sequencing method (31) identified several cDNAs with longer 5' extensions. 
The longest cDNA clone (clone 1.4) was used as a probe to map DMR-N9 
exons on previously isolated mouse cosmids, and to identify genomic subclones 
by standard hybridization detection assays (32). Briefly, exon containing 
genomic clones were generated by shotgun subcloning of random Sciu3A 
fragments or by specific subcloning of hybridizing restriction fragments of 
cosmid mDMRc8 (8) into plasmid vectors pGEM3 and pGEM4 (Promega) 
and pBluescript (Stratagene). Intron-e x o n  boundaries in these clones were 
determined by sequencing and comparison with cDNA sequences. Commer­
cially available T7, T3 or Sp6 transcription start site oligonucleotides or 
DMR-N9 specific synthetic oligonucleotides (Pharmacia) served as sequencing 
primers. Assembly, analysis and alignment of DNA and protein sequences 
were done using IG-SUITE 5.35 package (intelligenetics). Genbank (release 
83), EMBL (release 40), PIR-Protein (release 42) and SwissProt (release 30) 
databases were searched for homology using the BLAST program (33). The 
DMR-N9 sequences have been deposited in the EMBL database, accession 
numbers Z38011-Z38013 and Z38015.
Determination of transcription start site
The transcription start site of the DMR-N9 gene was determined using 
standard S]-nuclease mapping or primer elongation assays. Several different 
probes were used in the Sj-nuclease mapping. A Bamlil-Nco] genomic 
fragment (bp 1-534 in Fig. 1) was subcloned in pGEM4 and used to generate 
a single-stranded randomly labelled probe A. To this end, 4 |ig of supercoiled 
plasmid DNA was denatured and dissolved in 22 |il reaction mixture, 
containing 30 ng T7 primer and 3 jal lOXbuffer (70 mM Tris-H C l pH 7.5, 
70 mM M g C k  200 mM NaCl, 1 mM EDTA, 15 mM DTT). After 10 min at 
65 °C and 30 min at 37°C for primer annealing, 5 pi a - 33P-dCTP (Amersham, 
3000 Ci/mmol), 1 Jill 20 mM dATP, dGTP and dTTP and 2 }il Klenow enzyme 
(Boehringer Mannheim, 2 units/p.1) were added. The reaction was run for 15 
min at 37°C and then chased twice by the addition of 1 fit, 250 pM and 1 |il 
20 mM non-radioactive dCTP, respectively, at 15 min intervals at RT. After 
heat inactivation of the enzyme the reaction mix was incubated with £cv;Rl 
to linearize the double-stranded reaction product and the probe was run on a 
6% denaturing polyacrylamide geL The radioactive fragment of the appropriate 
length was excised and the DNA eluted in TE (10 mM Tris-HCl pH 8.0, 1 
mM EDTA) at 65°C. Probe B was a shorter genomic fragment, bracketed by 
the BcimH\ (at bp position 1) and the Nhel site (at bp position 410). This 
probe was end-labelled with y-32P-ATP (Amersham) and T4-polynucleotide 
kinase (BRL) at the NheI site and purified from LM agarose. The S ¡-nuclease 
protection assay was performed essentially as described by Berk and Sharp 
(34) and Weaver and Weissmann (35). Briefly, 0.01-0.03 pmol probe (30 000 
c.p.m. of probe A, or 10 000 c.p.m. of probe B) was hybridized to 25 pg 
total cellular RNA (mouse brain, liver, testis or intestine, or E.cali RNA) in 
80% FAHB (0.907 g formamide/ml, 400 mM NaCl, 40 mM PIPES pH 6.4,
1 mM EDTA) at 55°C. After 16 h hybridization the DNA—RNA complexes 
were digested for 45 min at 30°C with 75 units S¡-nuclease (Pharmacia) in 
250 pi digestion buffer (0.25 M NaCl, 0.03 M NaOAc pH 4.5, 1 mM ZnS0 4, 
12 |ig single-stranded carrier DNA per ml). Digestions were stopped by 
phenol/chloroform (1:1 v/v) extraction and protected DNA/RNA hybrids were 
alcohol precipitated and redissolved in 5 \x\ of 90% (v/v) formami de, 1 mM 
EDTA, 0.05% Bromophenol Blue and Xylene CyanoL After dénaturation by 
heating, reaction products were resolved on a 6% denaturing 
polyacrylamide—urea sequencing gel (aeryl/bisacryl 20: 1) and visualized 
by exposure to Kodak X-OMAT film, for 16 h to 2 weeks with one 
intensifying screen.
The primer elongation assay was performed as follows. The N9 specific 
primer, 5'-GGA.AGT.TGA.GGG.GCTAGC.A-3’, was located 200 bp 
upstream of the 5' end of cDNA clone 1.4 (see Fig. 1 ). One ng of 5' 32P end- 
labelled primer was mixed with 25 |dg total cellular RNA, in distilled water 
and denatured for 15 min at 65°C. Annealing and elongation was carried out 
in 50 mM T ris -H C l pH 8.3, 75 mM KCL 15 mM MgCl2, 0.01 mM DTT, 1 
mM of each of the dNTP's and 100 units MoMLV RT (BRL) for 1 h at 
37°C. The reaction product was precipitated, loaded on to a 6% denaturing 
polyacrylamide gel and visualized as described above.
Total cellular RNA used for these analyses was isolated from various tissues 
from adult mice, using the L iC l -u re a —SDS method (36).
RNA in situ hybridization
RNA in situ hybridization was performed as described by Büchner et al. (37) 
and van der Ven et a l  (submitted). 35S-CTP (Amersham) labelled transcripts 
were generated from the previously described cDNA clone 9.1 (8 ), linearized 
with EcoRl (anti-sense), or Kpnl (sense). T7 RNA polymerase (a kind gift of 
R.Hoet) or T 3 polymerase (Promega) were used to transcribe the antisense 
and sense probes under standard conditions (32).
ACKNOWLEDGEMENTS
We are grateful to Dr W.Hendriks for performing computer analyses. This 
work was supported by grants to B.W. by the American Muscular Dystrophy 
Association (MDA), the Dutch Beatrixfonds and NWO (grant 900-501-140) 
and the Association Française contre les Myopathies (AFM). H.H. and D.B. 
were supported by grants o f  the Deutsche Forschungsgemeinschaft.
REFERENCES
1. Harper, P.S. (1989) Myotonic dystrophy, 2nd edn. Saunders, London.
2. Brook, J.D., McCurrach, M.E., Harley, H.G., Buckler, A J., Church, D., 
Aburatani, H., Hunter, KM Stanton, V.P., Thirion, J.P., Hudson, T., 
Sohn, R., Zemelman, B., Snell, R.G., Rundle, S.A., Crow, S., Davies, J., 
Shelbourne, P., Buxton, J., Jones, C., Juvonen, V., Johnson, K., Harper, P.S., 
Shaw, D.J. and Housman, D.E. (1992) C ell  68, 799-808.
3. Mahadevan, M., Tsilfidis, C„ Sabourin, L., Shutler, G., Amemiya, C., 
Jansen, G., Neville, C., Narang, M., Barcel, J., CVHoy, K., Leblond, S., 
Earle-Macdonald, J., De Jong, PJ., Wieringa, B. and Korneluk, R.G. 
(1992) Science, 255, 1253-1255.
4. Fu, Y-H., Pizzuti, A., Fenwick, Jr, R.G., King, J., Rajnarayan, S., 
Dunne, P.W., Dübel, J., Nasser, G.A., Ashizawa, T., De Jong, P., 
Wieringa, B., Korneluk, R., Perryman, M.B., Epstein, H.F. and 
Thomas Caskey, C. (1992) Science, 255, 1256-1258.
5. Hunter, A., Tsilfidis, C., Mettler, G., Jacob, P., Mahadevan, M., Surh, L. 
and Korneluk, R.G. (1992) J. Med. Genet., 29, 774-779.
6. Brunner, H.G., Bruggenwirth, H.T., Nillesen, W., Jansen, G., 
Hamel, B.C.J., Hoppe, R.L.E., de Die, C.E.M., Howeler, C.J., van Oost, 
B.A., Wieringa, B., Ropers, H-H. and Smcets, H.J.M. (1993) Am. / . Hum. 
G e n e t 53, 1016-1023.
7. Harley, H.G., Rundle, S.A., MacMillan, J,CM Myring, J., Brook, J.D., 
Crow, S., Reardon, W., Fenton, I., Shaw, D.J. and Harper P.S. (1993) 
Am. J. Hum. G en e t , 52, 1164—1174.
8. Jansen, G„ Mahadevan, M., Amemiya, C., Wormskamp, N. Segers, B., 
Hendriks, W., O’Hoy, K., Baird, S., Sabourin, L., Lennon, G., Jap, P.L., 
Iles, D., Coerwmkel, M*, Hofker, M., Carrano, A.V., De Jong, PJ., 
Korneluk, R.G. and Wieringa, B. (1992) Nature Genet., 1, 261-266.
9. Mahadevan, M.S., Amemiya, C., Jansen, G., Sabourin, L, Baird, S., 
Neville, C.E., Wormskamp, N„ Segers, B., Batzer, M«, Lamerdin, J„ 
de Jong, P., Wieringa, B, and Korneluk, R.G. (1993) Hum. M ol Genet.,
2, 299-304.
10. Shaw, D.J., McCurrach, M., Rundle, S.A., Harley, H.H., Crow, S.R., 
Sohn, R., Thirion, J-R, Hamshere, M.G., Buckler, A.J., Harper, P.S., 
Housman, D.E. and Brook, J.D. (1993) Genomics, 18, 673-679.
IL van der Ven, P.F.M., Jansen, G., van Kuppevclt, T.H.M.S.M., 
Perryman, M.B., Lupa, M., Dunne, P.W., ter Laak, H.J., Jap, P.H.K., 
Veerkamp, J.H., Epstein, H.F. and Wieringa, B. (1993) Hum. M ol Genet.,
2, 1889-1894.
12. Dunne, P,W„ Walch, E.T. and Epstein, H.F. (1994) Biochemistry, 33, 
10809-10814.
13. Fu, Y-H., Friedman, D.L., Richards, S., Pearlman, J.A., Gibbs, R., 
Pizzuti, A., Ashizawa, T„ Perryman, M.B., Scartato, G., Fenwick, R.G. 
and Caskey, C.T. (1993) Science, 260, 235-238.
14. Hofmann-Radvanyi, H., Lavedan, C., Rabès, J-P., Savoy, D., Duros, C., 
Johnson, K. and Junien, C. (1993) Hum. M o l Genet., 2, 1263-1267.
15. Koga, R., Nakao, Y., Kurano, Y., Tsukahara, T., Nakamura, A., Ishiura, S., 
Nonaka, I. and Arahata, K. (1994) Biochem. Biophys. Res. Commun., 
202, 577-585.
16. Novelli, G., Gennarelli, M., Zelano, G., Pizzuti, A., Fattorini C., Caskey, X  
and Dallapiccola, B. (1993) Biochem. M ol B io l hitM 29, 291-297.
17. Roses, A.D., Schwartzbach, C.J., Taylor, H.P., Gilbert, J.R., Speer, M.C., 
Pericak-Vance, M.A., Jansen, G., Wieringa, B., Amemiya, C., de Jong, P. 
(1992) Am. J. Hum. Genet., 51, Supplement ASHG Meeting Abstract 
A109.
18. Sabourin, L.A., Mahadevan, M.S., Narang, M., Lee, D.S.C., Surh, L.C. 
and Korneluk, R.G. (1993) Nature Genet., 4, 233-238.
852 Human Molecular Genetics, i 995, Vol 4, No. 5
19. Ang, C.W. Y., Sabourin, L.A., Barcelo, J.M., Narang, M.A. and 
Korneluk, R.G. (1993), Am. J. Hum. G enet , 53, Supplement ASHG 
meeting Abstract 661.
20. Wang, Y-H., Amirhaeri, S., Kang, S., Wells, R. and Griffith, J.D. (1994) 
Science, 265, 669—671.
21. Jansen, G., Bartolomei, M., Kahlscheuer, V., Merkx, G., Wormskamp, N., 
Mariman, E., Smeets, D., Ropers, H-H. and Wieringa, B. (1993) Hum. 
M o l G ene t , 2, 1221-1229.
22. Kozak, M. (1987) J. M ol B io l , 196, 947-950.
23. Lockker, J, and Buzard, G. (1990) DNA Sequence, 1, 3-11.
24. Neer, E.J., Schmidt, C.J., Nambudripad, R. and Smith, T.F. (1994) Nature, 
371, 297-300.
25. van der Voorn, L. and Ploegh, H.L. (1992) FEBS L e tt , 307, 131-134.
26. Oakberg, E.F. (1956) Am. J. Anat,, 99, 391-414.
27. Wieringa, B. (1994) Hum. M o l Genet 3, 1-7.
28. Logan, J., Falck-Pedersen, E., Darnell, J.E., Jr. and Shenk, T. (1987) 
Proc. Natl A ca d  Sci. USA, 84, 8306-8310.
29. Jansen, G., Willems, P., Coerwinkel, M., Nillesen, W., SmeeUs, H., Vits, L., 
Höwelcr, C., Brunner, H. and Wieringa, B. (1994) Am. J. Hum . Genet, 
54, 575-585.
30. Barran, N„ McCurrach, M.E. and Manor, H. (1991) Proc. Natl Acad. Sci. 
USA , 88, 507-511.
31. Hattori, M. and Sakaki, Y. (1986) Anal Biochem., 152, 232-238.
32. Maniatis, T., Fritsch, E.F. and Sambrook, J. (1989) Molecular Cloning: 
A Labor at o íy  M anual 2nd edn. Cold Spring Harbor Press.
33. Altschul, S.F., Gish, W., Miller, W., Myers, E.W. and Lipman D.J. (1990) 
J . Mol. B io l , 215, 403-410.
34. Berk, A J .  and Sharp, P.A. (1977) Cell 12, 721-732.
35. Weaver, R. and Weissmann, C. (1979) Nucleic Acids Res., 7, 1175-1193.
36. Auffray, C. and Rougeon, F. (1980) Eur. J . B io c h e m 107, 303-314.
37. Büchner, D., Manca, A., Steinbach, P., WÖhrle, D., Just, W., Vogel, W., 
Hameister, H. and Poustka, A. (1993) Hum. Mol. G enet, 2, 2043-2050.
